Angioplasty or medical therapy in patients with documented ischemia

Original title: Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: A collaborative meta-analysis of contemporary randomized clinical trials. Reference: Stergiopoulos K el al. JAMA Intern Med 2013; DOI:10.1001/jamainternmed.2013

The amount in ischemic patients with stable coronary heart disease is associated with poor prognosis. However, it is unclear whether revascularization to reduce that amount also reduces ischemic events compared with medical treatment.

This meta- analysis included major works that randomized patients with stable coronary artery disease and demonstrated ischemia  to revascularization or medical treatment (MASS II , COURAGE , BARI 2D , FAME 2, etc.) . A total of 4064 patients, all with documented ischemia by stress test, gamma camera, echo stress or fractional flow reserve were analyzed. The endpoints included in the analysis were death from any cause, nonfatal myocardial infarction, urgent revascularization and angina. With a median follow-up of 5 years,  mortality rate from all causes was observed in the group receiving revascularization by angioplasty  versus  those who only received medical treatment  6.5 % and 7.3 % respectively (OR 0.90 CI 95% 0.71 to 1.16; p= ns) , nonfatal myocardial infarction 9.2 % and 7.6% (OR 1.24 CI 95% 0.99 to 1.56; p=ns) , urgent revascularization 18.3 % and  28.4 % (OR 0.64, CI 95% 0.35 to 1.17) and angina 20.3 % and 23.3 % (OR 0.91, CI 95% 0.57 to 1.44).

Conclusion:

In patients with stable coronary artery disease and documented ischemia, percutaneous revascularization does not seem to reduce events compared with medical treatment alone.

Editorial comment

This work, like all meta-analyzes, drag the limitations of the studies in which it was based. For example, ischemia was documented in all patients but as a binary variable. If we know that the greater ischemia increased mortality, why not also expect a different benefit with revascularization according to the amount. The same should be considered for symptoms; to worse major functional class a greater relief should be by revascularization. Finally the localization of the ischemic territory is taken into account in daily practice but has been difficult to differentiate in the works and should be taken into consideration. Perhaps some of these questions can be answered by the 8000 patients that ISCHEMIA study plans to include. 

SOLACI.ORG

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...